This Day On The Street
Continue to site right-arrow
ADVERTISEMENT
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here
Cramer's Action Alerts PLUS - See his portfolio and get alerts BEFORE every trade. Learn more NOW!

Boom Or Bubble? Insiders Like The Look Of These 3 Biotech Stocks

1. BioSpecifics Technologies Corp. ( BSTC): Involves in the development of an injectable collagenase for various indications.

Market cap at $122.84M, most recent closing price at $19.39.

Over the last six months, insiders were net buyers of 178,265 shares, which represents about 4.54% of the company's 3.93M share float.

Since October 7 th, BioSpecifics Technologies has returned 0.73%, while fellow biotechnology companies Gilead Sciences Inc. (GILD) and Amgen Inc. (AMGN) have returned 9.05% and 2.82%, respectively.

In the pipeline:

On October 23 rd, BioSpecifics Technologies announced the start of its Phase 2a study for cellulite treatment. XIAFLEX, the company's injectable collagenase that is approved for treating Dupuytren's contracture in the US, is being used in the study, and results are expected to be released in the first quarter of 2015.

Between 70-90% of women have cellulite (it's quite rare in men), and US consumers spend millions of dollars annually trying to get rid of it. The Food and Drug Administration (FDA) has yet to approve any pharmaceutical treatments for cellulite.

 

2. MannKind Corp. ( MNKD): Focuses on the discovery, development, and commercialization of therapeutic products for diabetes and cancer.

Market cap at $1.33B, most recent closing price at $4.68.

Over the last six months, insiders were net buyers of 39,896,322 shares, which represents about 24.14% of the company's 165.29M share float.

MannKind has returned -7.71% over the last month. Its performance surpasses that of competitors Threshold Pharmaceuticals Inc. (THLD) and Merrimack Pharmaceuticals, Inc. (MACK), but falls short of Amgen's 2.82% and BioSpecifics Technologies' 0.73%.

In the pipeline:

At the end of October, the FDA acknowledged Mannkind's resubmitted new drug application for Afrezza, the company's highly anticipated inhalable insulin treatment. The FDA scheduled Afrezza's Prescription Drug User Fee Act (PDUFA) date for April 15, which is when Mannkind will have to pay fees for its New Drug Application. COO Hakan Edstrom viewed the PDUFA date as a positive development, stating "the FDA's two-week action to set the PDUFA date is the agency's regular positive response at this point in today's regulatory process."

Presently 347 million people worldwide suffer from diabetes, and that number will only grow as the disease likely becomes the 7th leading cause of death by 2030. Furthermore, according to  Research and Markets, the global diabetes drug industry is expected to swell to $56.9 billion in 2018.

 

2 of 3

Check Out Our Best Services for Investors

Action Alerts PLUS

Portfolio Manager Jim Cramer and Director of Research Jack Mohr reveal their investment tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
Quant Ratings

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
Stocks Under $10

David Peltier uncovers low dollar stocks with serious upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
14-Days Free
Try it NOW
Only $9.95
Try it NOW
14-Days Free
Try it NOW

Check Out Our Best Services for Investors

Dividend Stock Advisor

David Peltier identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Updates with exact steps to take - BUY, HOLD, SELL
Trifecta Stocks

Every recommendation goes through 3 layers of intense scrutiny—quantitative, fundamental and technical analysis—to maximize profit potential and minimize risk.

Product Features:
  • Model Portfolio
  • Intra Day Trade alerts
  • Access to Quant Ratings
Options Profits

Our options trading pros provide over 100 monthly option trading ideas and strategies to help you become a well-seasoned trader.

Product Features:
  • Actionable options commentary and news
  • Real-time trading community
Try it NOW
Try it NOW
Try it NOW
To begin commenting right away, you can log in below using your Disqus, Facebook, Twitter, OpenID or Yahoo login credentials. Alternatively, you can post a comment as a "guest" just by entering an email address. Your use of the commenting tool is subject to multiple terms of service/use and privacy policies - see here for more details.
Submit an article to us!
SYM TRADE IT LAST %CHG

Markets

DOW 18,065.46 -137.91 -0.76%
S&P 500 2,090.25 -17.53 -0.83%
NASDAQ 4,944.3970 -35.5040 -0.71%

Partners Compare Online Brokers

Free Reports

Free Newsletters from TheStreet

My Subscriptions:

After the Bell

Before the Bell

Booyah! Newsletter

Midday Bell

TheStreet Top 10 Stories

Winners & Losers

Register for Newsletters
Top Rated Stocks Top Rated Funds Top Rated ETFs